Ole Mogensen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1271619/publications.pdf

Version: 2024-02-01

102 papers 2,664 citations

168829 31 h-index 263392 45 g-index

104 all docs

 $\begin{array}{c} 104 \\ \\ \text{docs citations} \end{array}$

104 times ranked 3724 citing authors

#	Article	IF	CITATIONS
1	SENTIREC – The sentinel node mapping in women with cervical cancer study – Patient-reported early lymphedema and its impact on quality of life. Gynecologic Oncology, 2022, 164, 463-472.	0.6	6
2	Identification of endometrial cancer recurrence $\hat{a}\in \hat{u}$ a validated algorithm based on nationwide Danish registries. Acta Oncol \tilde{A}^3 gica, 2021, 60, 452-458.	0.8	6
3	Trends in Hysterectomy Incidence Rates During 2000–2015 in Denmark: Shifting from Abdominal to Minimally Invasive Surgical Procedures. Clinical Epidemiology, 2021, Volume 13, 407-416.	1.5	22
4	Post robotic investment: Cost consequences and impact on length of stay for obese women with endometrial cancer. Acta Obstetricia Et Gynecologica Scandinavica, 2021, 100, 1830-1839.	1.3	0
5	From FIGO-2009 to FIGO-2018 in women with early-stage cervical cancer; Does the revised staging reflect risk groups?. Gynecologic Oncology, 2021, 163, 281-288.	0.6	7
6	Sentinel lymph node mapping in early-stage cervical cancer – A national prospective multicenter study (SENTIREC trial). Gynecologic Oncology, 2021, 162, 546-554.	0.6	15
7	Clinical impact of preâ€treatment FDGâ€PET/CT staging of primary ovarian, fallopian tube, and peritoneal cancers in women. Acta Obstetricia Et Gynecologica Scandinavica, 2020, 99, 186-195.	1.3	7
8	Uterine fibroids increase time to pregnancy: a cohort study. European Journal of Contraception and Reproductive Health Care, 2020, 25, 37-42.	0.6	9
9	Temporality and timework: Danish endometrial cancer patients' experiences of an accelerated cancer patient pathway. Time and Society, 2020, 29, 866-891.	0.8	2
10	Relationship between a uterine fibroid diagnosis and the risk of adverse obstetrical outcomes: a cohort study. BMJ Open, 2020, 10, e032104.	0.8	16
11	Prophylactic incisional negative pressure wound therapy reduces the risk of surgical site infection after caesarean section in obese women: a pragmatic randomised clinical trial. BJOG: an International Journal of Obstetrics and Gynaecology, 2019, 126, 628-635.	1.1	66
12	"But this is a good cancer:―Patient perceptions of endometrial cancer in Denmark. Journal of Clinical Nursing, 2019, 28, 245-256.	1.4	4
13	How Do We Follow Up Patients With Endometrial Cancer?. Current Oncology Reports, 2019, 21, 57.	1.8	12
14	Long term resource consequences of a nationwide introduction of robotic surgery for women with early stage endometrial cancer. Gynecologic Oncology, 2019, 154, 411-419.	0.6	8
15	Surgery Is Physically Demanding and Associated With Multisite Musculoskeletal Pain: AÂCross-Sectional Study. Journal of Surgical Research, 2019, 240, 30-39.	0.8	35
16	Feeling lucky: hierarchies of suffering and stories of endometrial cancer in a Danish context. Sociology of Health and Illness, 2019, 41, 950-964.	1.1	9
17	Nationwide Introduction of Minimally Invasive Robotic Surgery for Early-Stage Endometrial Cancer and Its Association With Severe Complications. JAMA Surgery, 2019, 154, 530.	2.2	51
18	Survival after a nationwide introduction of robotic surgery in women with early-stage endometrial cancer: aÂpopulation-based prospective cohort study. European Journal of Cancer, 2019, 109, 1-11.	1.3	42

#	Article	IF	CITATIONS
19	Costâ€effectiveness of incisional negative pressure wound therapy compared with standard care after caesarean section in obese women: a trialâ€based economic evaluation. BJOG: an International Journal of Obstetrics and Gynaecology, 2019, 126, 619-627.	1.1	37
20	Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer. Oncolmmunology, 2019, 8, e1535730.	2.1	57
21	Self-assessment of Goal Achievements Within a Gynecological Cancer Rehabilitation Counseling. Cancer Nursing, 2019, 42, 58-66.	0.7	9
22	Surgeons' muscle load during robotic-assisted laparoscopy performed with a regular office chair and the preferred of two ergonomic chairs: A pilot study. Applied Ergonomics, 2019, 78, 286-292.	1.7	18
23	Fertility after uterine artery embolization of fibroids: a systematic review. Archives of Gynecology and Obstetrics, 2018, 297, 13-25.	0.8	83
24	Authors' reply re: Patientâ€initiated followâ€up affects fear of recurrence and health care use: a randomised trial in earlyâ€stage endometrial cancer. BJOG: an International Journal of Obstetrics and Gynaecology, 2018, 125, 1778-1779.	1.1	2
25	A systematic review about costing methodology in robotic surgery: evidence for low quality in most of the studies. Health Economics Review, 2018, 8, 21.	0.8	18
26	Patientâ€initiated follow up affects fear of recurrence and healthcare use: a randomised trial in earlyâ€stage endometrial cancer. BJOG: an International Journal of Obstetrics and Gynaecology, 2018, 125, 1705-1714.	1.1	43
27	First child's impact on parental relationship: an existential perspective. BMC Pregnancy and Childbirth, 2018, 18, 157.	0.9	14
28	Musculoskeletal pain among surgeons performing minimally invasive surgery: a systematic review. Surgical Endoscopy and Other Interventional Techniques, 2017, 31, 516-526.	1.3	55
29	Systematic review of sameâ€day discharge after minimally invasive hysterectomy. International Journal of Gynecology and Obstetrics, 2017, 136, 128-137.	1.0	82
30	Detection of recurrence in early stage endometrial cancer – the role of symptoms and routine follow-up. Acta Oncológica, 2017, 56, 262-269.	0.8	30
31	Metastatic endometrial endometrioid carcinoma mimicking pilomatrixoma of the distal vagina. BMJ Case Reports, 2017, 2017, bcr2016217938.	0.2	2
32	The nature of early-stage endometrial cancer recurrenceâ€"A national cohort study. European Journal of Cancer, 2016, 69, 51-60.	1.3	41
33	Is HPV vaccination in pregnancy safe?. Human Vaccines and Immunotherapeutics, 2016, 12, 1960-1964.	1.4	20
34	Prayer and meditation among Danish first time mothersâ€"a questionnaire study. BMC Pregnancy and Childbirth, 2016, 16, 8.	0.9	13
35	Trends in gynecologic cancer among elderly women in Denmark, 1980–2012. Acta Oncológica, 2016, 55, 65-73.	0.8	18
36	FDG PET/CT in cancer: comparison of actual use with literature-based recommendations. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 695-706.	3.3	46

3

#	Article	IF	Citations
37	Priority Setting for Improvement of Cervical Cancer Prevention in Iran. International Journal of Health Policy and Management, 2016, 5, 225-232.	0.5	33
38	Predictors of mortality within 1 year after primary ovarian cancer surgery: a nationwide cohort study. BMJ Open, 2016, 6, e010123.	0.8	11
39	Video-, Audio-, and Computer-Mediated Education of Patients and Relatives in Gynecologic Cancer Care. Cancer Nursing, 2015, 38, E42-E52.	0.7	5
40	Needs and priorities of women with endometrial and cervical cancer. Journal of Psychosomatic Obstetrics and Gynaecology, 2015, 36, 122-132.	1.1	34
41	Healthcare professionals experience with motivational interviewing in their encounter with obese pregnant women. Midwifery, 2015, 31, 678-684.	1.0	23
42	Vaginal vault recurrences of endometrial cancer in non-irradiated patients â€" Radiotherapy or surgery. Gynecologic Oncology Reports, 2015, 11, 26-30.	0.3	19
43	Cervical cancer screening in the Faroe Islands. Acta Oncológica, 2015, 54, 210-216.	0.8	2
44	Goal setting in cancer rehabilitation and relation to quality of life among women with gynaecological cancer. Acta Oncol \tilde{A}^3 gica, 2015, 54, 1814-1823.	0.8	14
45	[18F]Fluorodeoxyglucose PET/Computed Tomography in Breast Cancer and Gynecologic Cancers. PET Clinics, 2015, 10, 89-104.	1.5	11
46	Training in motivational interviewing in obstetrics: a quantitative analytical tool. Acta Obstetricia Et Gynecologica Scandinavica, 2014, 93, 698-704.	1.3	15
47	Lymphadenectomy in surgical stage I epithelial ovarian cancer. Acta Obstetricia Et Gynecologica Scandinavica, 2014, 93, 256-260.	1.3	13
48	Supportive Care Needs for Women With Gynecological Cancer and Their Relatives During the Prediagnostic Period. Cancer Nursing, 2014, 37, 457-467.	0.7	12
49	The Value of Random Biopsies, Omentectomy, and Hysterectomy in Operations for Borderline Ovarian Tumors. International Journal of Gynecological Cancer, 2014, 24, 874-879.	1.2	22
50	Existential Meaning Among First-Time Full-Term and Preterm Mothers. Journal of Perinatal and Neonatal Nursing, 2014, 28, 271-279.	0.5	16
51	Primary Surgery or Interval Debulking for Advanced Epithelial Ovarian Cancer: Does It Matter?. International Journal of Gynecological Cancer, 2014, 24, 1420-1428.	1.2	29
52	The potential role of HPV vaccination in the prevention of infectious complications of pregnancy. Expert Review of Vaccines, 2014, 13, 1307-1316.	2.0	14
53	Making existential meaning in transition to motherhoodâ€"A scoping review. Midwifery, 2014, 30, 733-741.	1.0	85
54	Feasibility of a Psychosocial Rehabilitation Intervention to Enhance the Involvement of Relatives in Cancer Rehabilitation: Pilot Study for a Randomized Controlled Trial. Patient, 2013, 6, 201-212.	1.1	22

#	Article	IF	CITATIONS
55	Salpingectomy as standard at hysterectomy? A Danish cohort study, 1977–2010. BMJ Open, 2013, 3, e002845.	0.8	19
56	Hope Pictured in Drawings by Women Newly Diagnosed With Gynecologic Cancer. Cancer Nursing, 2013, 36, E42-E50.	0.7	12
57	The experience of pregnant women with a body mass index >30Âkg/m ² of their encounters with healthcare professionals. Acta Obstetricia Et Gynecologica Scandinavica, 2013, 92, 1101-1107.	1.3	49
58	A New Method for Analyzing Diagnostic Delay in Gynecological Cancer. International Journal of Gynecological Cancer, 2012, 22, 712-717.	1.2	15
59	Gynecological cancer patients' differentiated use of help from a nurse navigator: a qualitative study. BMC Health Services Research, 2012, 12, 168.	0.9	16
60	Survival after stage IA endometrial cancer; can followâ€up be altered? A prospective nationwide Danish survey. Acta Obstetricia Et Gynecologica Scandinavica, 2012, 91, 976-982.	1.3	49
61	Reproducibility of mass spectrometry based protein profiles for diagnosis of ovarian cancer across clinical studies: A systematic review. Journal of Proteomics, 2012, 75, 2758-2772.	1.2	16
62	Reasons for Diagnostic Delay in Gynecological Malignancies. International Journal of Gynecological Cancer, 2011, 21, 967-974.	1.2	45
63	Benefits and challenges perceived by patients with cancer when offered a nurse navigator. International Journal of Integrated Care, 2011, 11, e130.	0.1	19
64	Serum peptide/protein profiling by mass spectrometry provides diagnostic information independently of CA125 in women with an ovarian tumor. Cancer Biomarkers, 2010, 6, 73-82.	0.8	4
65	The value of gynecologic cancer follow-up: evidence-based ignorance?. International Journal of Gynecological Cancer, 2010, 20, 1307-20.	1.2	39
66	Expression of the Epidermal Growth Factor System in Eutopic Endometrium from Women with Endometriosis Differs from That in Endometrium from Healthy Women. Gynecologic and Obstetric Investigation, 2009, 67, 118-126.	0.7	16
67	Gene expression metaâ€analysis identifies chromosomal regions involved in ovarian cancer survival. Genes Chromosomes and Cancer, 2009, 48, 711-724.	1.5	13
68	Serum protein profiling by solid phase extraction and mass spectrometry: A future diagnostics tool?. Proteomics, 2009, 9, 1428-1441.	1.3	98
69	The meaning of hope in nursing research: a metaâ€synthesis. Scandinavian Journal of Caring Sciences, 2009, 23, 549-557.	1.0	78
70	Improvement of women's health – HPV vaccination after 16 years of age?. Acta Obstetricia Et Gynecologica Scandinavica, 2009, 88, 756-757.	1.3	2
71	Hope as experienced in women newly diagnosed with gynaecological cancer. European Journal of Oncology Nursing, 2009, 13, 274-279.	0.9	29
72	Gene Expression Profiles as Prognostic Markers in Women With Ovarian Cancer. International Journal of Gynecological Cancer, 2009, 19, 1205-1213.	1.2	12

#	Article	IF	Citations
73	Reproducibility of serum protein profiling by systematic assessment using solidâ€phase extraction and matrixâ€assisted laser desorption/ionization mass spectrometry. Rapid Communications in Mass Spectrometry, 2008, 22, 291-300.	0.7	32
74	Reproducibility of Mass Spectrometry Based Protein Profiles for Diagnosis of Breast Cancer across Clinical Studies: A Systematic Review. Journal of Proteome Research, 2008, 7, 1395-1402.	1.8	47
75	Combined Experimental and Statistical Strategy for Mass Spectrometry Based Serum Protein Profiling for Diagnosis of Breast Cancer: A Case-Control Study. Journal of Proteome Research, 2008, 7, 1419-1426.	1.8	42
76	Accuracy of Preoperative Tumor Grade and Intraoperative Gross Examination of Myometrial Invasion in Patients with Endometrial Cancer. Obstetrical and Gynecological Survey, 2007, 62, 583-584.	0.2	0
77	RNA quality and gene expression analysis of ovarian tumor tissue undergoing repeated thaw–freezing. Experimental and Molecular Pathology, 2007, 82, 95-102.	0.9	23
78	Expression of the epidermal growth factor system in endometrioid endometrial cancer. Gynecologic Oncology, 2007, 104, 158-167.	0.6	49
79	Accuracy of preoperative tumor grade and intraoperative gross examination of myometrial invasion in patients with endometrial cancer. Acta Obstetricia Et Gynecologica Scandinavica, 2007, 86, 739-741.	1.3	47
80	Carcinoma in situ cervicis uteri and inheritance—A Danish twin study. Gynecologic Oncology, 2006, 103, 688-691.	0.6	3
81	Chemotherapy-induced changes of CA 125 in patients with epithelial ovarian cancer. Gynecologic Oncology, 2005, 97, 410-412.	0.6	7
82	Serum protein profiling by miniaturized solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometry. Rapid Communications in Mass Spectrometry, 2005, 19, 1578-1586.	0.7	50
83	Expression of the epidermal growth factor system in human endometrium during the menstrual cycle. Molecular Human Reproduction, 2005, 11, 543-551.	1.3	55
84	Management of ovarian cysts. Acta Obstetricia Et Gynecologica Scandinavica, 2004, 83, 1012-1021.	1.3	40
85	Management of ovarian cysts. Acta Obstetricia Et Gynecologica Scandinavica, 2004, 83, 1012-1021.	1.3	4
86	The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer. Anticancer Research, 2002, 22, 1765-8.	0.5	17
87	Telomerase activity, MIB-1, PCNA, HPV 16 and p53 as diagnostic markers for cervical intraepithelial neoplasiaNote. Apmis, 2001, 109, 607-617.	0.9	27
88	Neural networks in the diagnosis of malignant ovarian tumours. BJOG: an International Journal of Obstetrics and Gynaecology, 1999, 106, 1078-1082.	1.1	24
89	Elevated Serum Insulin-Like Growth Factor-Binding Protein 2 (IGFBP-2) and Decreased IGFBP-3 in Epithelial Ovarian Cancer: Correlation with Cancer Antigen 125 and Tumor-Associated Trypsin Inhibitor1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2308-2313.	1.8	95
90	Tissue Polypeptide-Specific Antigen (TPS) as Tumour Marker in Epithelial Ovarian Cancer. Acta Oncol $ ilde{A}^3$ gica, 1997, 36, 433-435.	0.8	5

#	Article	IF	CITATIONS
91	Elevated Serum Insulin-Like Growth Factor-Binding Protein 2 (IGFBP-2) and Decreased IGFBP-3 in Epithelial Ovarian Cancer: Correlation with Cancer Antigen 125 and Tumor-Associated Trypsin Inhibitor. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2308-2313.	1.8	74
92	Predictive and Prognostic Values of Cancer-Associated Serum Antigen (CASA) and Cancer Antigen 125 (CA 125) Levels Prior to Second-Look Laparotomy for Ovarian Cancer. Gynecologic Oncology, 1995, 59, 251-254.	0.6	10
93	The Role of Serum Tetranectin, CA 125, and a Combined Index as Tumor Markers in Women with Pelvic Tumors. Gynecologic Oncology, 1995, 56, 22-28.	0.6	23
94	Prognostic value of CA 125 in advanced ovarian cancer. Gynecologic Oncology, 1992, 44, 207-212.	0.6	67
95	Predictive value of CA 125 during early chemotherapy of advanced ovarian cancer. Gynecologic Oncology, 1990, 37, 44-46.	0.6	35
96	Tumor-associated trypsin inhibitor and cancer antigen 125 in pelvic masses. Gynecologic Oncology, 1990, 38, 170-174.	0.6	11
97	Alpha1-acid glucoprotein in ovarian cancer with a reference to immunosuppressive acidic protein and cancer antigen 125. Cancer, 1989, 64, 1867-1871.	2.0	8
98	False positive results in an enzyme immunometric assay for the ovarian cancer associated antigen CA 125. European Journal of Cancer & Clinical Oncology, 1989, 25, 129-131.	0.9	9
99	CA 125 in the diagnosis of pelvic masses. European Journal of Cancer & Clinical Oncology, 1989, 25, 1187-1190.	0.9	13
100	Preoperative Measurement of Cancer Antigen 125 (CA 125) in the Differential Diagnosis of Ovarian Tumors. Acta Oncol \tilde{A}^3 gica, 1989, 28, 471-473.	0.8	7
101	Measurement of the ovarian cancer-associated antigen CA 125 prior to second look operation. European Journal of Cancer & Clinical Oncology, 1988, 24, 1835-1837.	0.9	19
102	Tumor markers in ovarian cancer: A comparison between immunosuppressive acidic protein and $\hat{l}\pm 1$ -acid glycoprotein. American Journal of Obstetrics and Gynecology, 1986, 154, 1165-1166.	0.7	5